MAGIC, 2001 trial summary

A randomised clinical trial investigating the effect of myoblasts versus placebo in patient with severe ischaemic heart failure

Lancet 2001;357:279-80  




Studied treatment autologous skeletal myoblasts into the postinfarction scar during coronary artery bypass grafting of remote myocardial areas
Control treatment placebo
cell type Skeletal myoblasts
Cell injection procedure Epimyocardial



Patients patient with severe ischaemic heart failure
Group sizes 63 / 34



Blindness Inclusion period
Follow-up duration 6 mo Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI Minnesota Living With Heart Failure Questionnaire - -9 - -9 no data 6-min Walk, m - 53 - 30 no data all-cause mortality 9 63 2 34 Out of scale2,43[0,49; 11,95] LVEF - 53 - 30 no data acute heart failure - -9 - -9 no data LV End-Systolic Volume - -9 - -9 no data ventricular tachycardia 9 63 2 34 Out of scale2,43[0,49; 11,95] NT-proBNP - -9 - -9 no data NYHA deterioration - -9 - -9 no data Peak VO2 (mL/kg/min) - -9 - -9 no data NYHA class - -9 - -9 no data cardiac event - 63 - 34 no data0,22,01,0


MenaschĂ© P, Hagège AA, Scorsin M, Pouzet B, Desnos M, Duboc D, Schwartz K, Vilquin JT, Marolleau JP Myoblast transplantation for heart failure. Lancet 2001;357:279-80     [PMID: 11214133]   link to pdf  



Registering number (see trial on clinicaltrials.gov)
Code Name

 




Appears in following systematic reviews: